IFNA1 and coinfection: General safety of BLV at a standard dose for at least 48 weeks with or without Peg-IFNα was also recently demonstrated in people living with HIV and HBV/HDV co-infection, without evidence of serious adverse events due to DDIs with anti-HIV drugs and with further evidence of increased effectiveness in the Peg-IFNα arm.